ACAD: ACADIA Pharmaceuticals, Inc.
About
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Current Value
$16.251 Year Return
Current Value
$16.251 Year Return
Key Details
Market Cap
$2.70B
P/E Ratio
20.98
1Y Stock Return
-27.80%
1Y Revenue Growth
47.06%
Dividend Yield
0.00%
Price to Book
4.7
Strategies that include ACAD
Stock's related to ACAD
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STTK | 52.09% | $54.42M | -50.22% | 0.00% |
| VRTX | 50.04% | $115.38B | +26.28% | 0.00% |
| ABM | 45.99% | $3.48B | +35.26% | 1.62% |
| PLAB | 42.91% | $1.52B | +12.34% | 0.00% |
| PRTA | 42.03% | $756.01M | -56.52% | 0.00% |
| CLNE | 41.55% | $589.93M | -23.92% | 0.00% |
| HBNC | 41.24% | $788.62M | +64.30% | 3.57% |
| PGEN | 40.69% | $228.91M | -28.00% | 0.00% |
| ALEX | 39.96% | $1.41B | +18.14% | 4.59% |
| MODG | 38.82% | $1.56B | -25.89% | 0.00% |
| VBTX | 38.33% | $1.58B | +53.68% | 2.75% |
| DAWN | 38.06% | $1.36B | +13.42% | 0.00% |
| RGNX | 37.94% | $473.65M | -51.96% | 0.00% |
| ASH | 37.93% | $3.73B | -1.96% | 2.08% |
| OPEN | 37.77% | $1.14B | -31.62% | 0.00% |
| FOLD | 37.70% | $2.84B | -11.52% | 0.00% |
| UVSP | 37.37% | $891.91M | +64.40% | 2.76% |
| GPRO | 37.33% | $179.52M | -67.23% | 0.00% |
| LILA | 37.32% | $1.37B | +2.95% | 0.00% |
| ENOV | 37.17% | $2.53B | -10.59% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LPTH | -0.01% | $62.27M | +33.05% | 0.00% |
| HLN | -0.04% | $42.91B | +13.94% | 1.67% |
| ANGI | 0.07% | $987.36M | -5.71% | 0.00% |
| COR | 0.09% | $47.48B | +21.20% | 0.86% |
| VSTA | -0.10% | $204.94M | -39.33% | 0.00% |
| COCO | 0.13% | $2.01B | +24.49% | 0.00% |
| NHTC | -0.20% | $61.83M | +0.19% | 14.81% |
| SRRK | -0.21% | $2.61B | +134.91% | 0.00% |
| AJG | -0.22% | $64.17B | +17.51% | 0.80% |
| NFE | 0.25% | $2.29B | -74.75% | 3.32% |
| TEO | -0.28% | $1.69B | +87.97% | 0.00% |
| CRTO | -0.28% | $2.10B | +58.23% | 0.00% |
| LITB | 0.29% | $35.48M | -75.45% | 0.00% |
| CARV | 0.30% | $8.48M | -8.79% | 0.00% |
| SSSS | 0.30% | - | - | 0.00% |
| BACK | -0.30% | $1.76M | -32.90% | 0.00% |
| OKLO | 0.31% | $2.66B | +111.04% | 0.00% |
| ARLP | 0.31% | $3.54B | +26.77% | 10.11% |
| AWH | 0.32% | $11.44M | -76.87% | 0.00% |
| AGS | 0.32% | $479.25M | +57.18% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DT | -19.53% | $15.40B | -1.30% | 0.00% |
| PRPO | -16.19% | $9.10M | -13.65% | 0.00% |
| LPLA | -15.81% | $23.55B | +38.13% | 0.38% |
| HUSA | -12.72% | $16.69M | -11.56% | 0.00% |
| VIST | -12.31% | $4.75B | +67.10% | 0.00% |
| ZCMD | -12.13% | $2.80M | -88.67% | 0.00% |
| AXON | -11.54% | $46.53B | +167.14% | 0.00% |
| TCTM | -10.41% | $8.10M | -42.99% | 0.00% |
| PGR | -10.23% | $149.10B | +57.29% | 0.45% |
| TXO | -9.96% | $737.26M | -1.80% | 13.22% |
| FTNT | -9.83% | $69.59B | +72.67% | 0.00% |
| IBKR | -9.09% | $20.20B | +131.83% | 0.37% |
| TH | -9.08% | $839.02M | -24.49% | 0.00% |
| INSP | -8.73% | $5.28B | +27.64% | 0.00% |
| RNR | -8.52% | $13.74B | +23.09% | 0.58% |
| ZTO | -8.11% | $12.58B | -4.71% | 4.73% |
| CME | -7.93% | $82.76B | +9.21% | 1.98% |
| VITL | -7.45% | $1.32B | +142.79% | 0.00% |
| HIHO | -7.39% | $8.63M | 0.00% | 6.12% |
| LTRN | -5.97% | $33.22M | -22.61% | 0.00% |
ETF's related to ACAD
News
Finnhub
SAN DIEGO - Acadia Pharmaceuticals Inc. today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors granted inducement awards consisting of non-qualified...
Yahoo
SAN DIEGO, November 15, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units ("RSUs") to twenty-three new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new emplo
Yahoo
The United States market has shown robust performance recently, with a 3.9% increase over the last week and a remarkable 33% rise over the past year, while earnings are projected to grow by 16% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on these favorable market conditions.
SeekingAlpha
Analysis of ACADIA Pharmaceuticals Inc., a mid-cap biopharma stock that recently surged 20% post-Q3 results. Click for my post earnings look at ACAD shares.
Finnhub
Acadia Corporate Presentation November 2024 Forward-Looking Statements ...
Yahoo
It's been a pretty great week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with its shares surging 19...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.